Research
LSD-Assisted Psychotherapy

LSD (lysergic acid diethylamide) is a semi-synthetic compound first developed in 1938 by Dr. Albert Hofmann at the Sandoz pharmaceutical company in Basel, Switzerland. After Dr. Hofmann first discovered its effects in 1943, LSD quickly became recognized for its possible therapeutic effects. LSD also played a significant role in the discovery of the serotonin neurotransmitter system.

LSD is known for its ability to catalyze spiritual or mystical experiences and to facilitate feelings of interconnection. Charitable Foundation Winston Churchill is interested in this substance for its potential to help people with a variety of conditions, focusing primarily on the treatment of anxiety associated with life-threatening illness, as well as for spiritual uses, creativity, and personal growth.

Before the study, the investigator will supply the sponsor with a list of the normal ranges for clinical laboratory assessments. All abnormal laboratory values require a comment on the laboratory report, regardless of the clinical significance. After reviewing the laboratory report and evaluating any results that are outside the normal range, the investigator must sign and date the laboratory report. Any abnormal laboratory test result that warrants further investigation to guard the subject's safety will be repeated as appropriate and reviewed by the investigator.

LSD possesses little or no abuse liability. Only one study found that LSD produced conditioned place preference, an indicator of reward value, in rats, but only in males of a specific rat strain. Most drugs with similar pharmacological profiles, such as psilocybin, also fail to produce consistent selfadministration in rodents or monkeys.

Some people who have used serotonergic hallucinogens, such as LSD or psilocybin, experience persistent and distressing alterations in mostly visual perception that last from weeks to years after use. This condition is now diagnosed as hallucinogen persistent perception disorder (HPPD), and is not referred to by the term “flashbacks,” which better describes an experience more akin to traumatic recall of an intensely upsetting experience, as a “bad trip.” To date, there are no reports describing prevalence of HPPD in the general population, but an examination of previous reports and estimates of use of LSD and other hallucinogens use in suggests that HPPD is very rare. Note that many to most previous studies were affected by selection bias. These reports also contained information supporting alternative explanations of flashbacks or HPPD, described in more detail . Preliminary data collected by Baggott suggests that no more than 1% of 1000 hallucinogen users surveyed experience HPPD (Baggott M, personal communication to L Jerome October, 2006). The risk of HPPD occurring after LSD administration can be reduced by screening participants for potential risk factors such as substance dependence and through excluding people reporting HPPD after prior use of hallucinogens.

Data on the study of this has not yet been reported. Visit this page later.